Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021409 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2025010 | 0.90 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2023132 | 0.90 | HCRTR2 (0.86) | HCRTR2HCRTR1 | |
| SCHEMBL2026216 | 0.85 | HCRTR2 (0.81) | HCRTR2HCRTR1 | |
| SCHEMBL12641257 | 0.85 | HCRTR2 (0.78) | HCRTR2HCRTR1 | |
| SCHEMBL2027748 | 0.85 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2025307 | 0.85 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2024133 | 0.85 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2024882 | 0.85 | HCRTR2 (0.80) | HCRTR2HCRTR1 | |
| SCHEMBL2028385 | 0.85 | HCRTR2 (1.00) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | claimed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | claimed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | claimed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | claimed |
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | HCRTR2 3205/4885HCRTR1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.